Optimization of Diagnosis and Treatment of Hematological Diseases Via Artificial Intelligence

Overview

Journal Front Med (Lausanne)

Specialty General Medicine

Date 2024 Nov 22

PMID 39574909

Authors

Shi-Xuan Wang

Zou-Fang Huang

Jing Li

Yin Wu

Jun Du

Ting Li

Affiliations

Soon will be listed here.

Abstract

Background: Optimizing the diagnosis and treatment of hematological diseases is a challenging yet crucial research area. Effective treatment plans typically require the comprehensive integration of cell morphology, immunology, cytogenetics, and molecular biology. These plans also consider patient-specific factors such as disease stage, age, and genetic mutation status. With the advancement of artificial intelligence (AI), more "AI + medical" application models are emerging. In clinical practice, many AI-assisted systems have been successfully applied to the diagnosis and treatment of hematological diseases, enhancing precision and efficiency and offering valuable solutions for clinical practice.

Objective: This study summarizes the research progress of various AI-assisted systems applied in the clinical diagnosis and treatment of hematological diseases, with a focus on their application in morphology, immunology, cytogenetics, and molecular biology diagnosis, as well as prognosis prediction and treatment.

Methods: Using PubMed, Web of Science, and other network search engines, we conducted a literature search on studies from the past 5 years using the main keywords "artificial intelligence" and "hematological diseases." We classified the clinical applications of AI systems according to the diagnosis and treatment. We outline and summarize the current advancements in AI for optimizing the diagnosis and treatment of hematological diseases, as well as the difficulties and challenges in promoting the standardization of clinical diagnosis and treatment in this field.

Results: AI can significantly shorten turnaround times, reduce diagnostic costs, and accurately predict disease outcomes through applications in image-recognition technology, genomic data analysis, data mining, pattern recognition, and personalized medicine. However, several challenges remain, including the lack of AI product standards, standardized data, medical-industrial collaboration, and the complexity and non-interpretability of AI systems. In addition, regulatory gaps can lead to data privacy issues. Therefore, more research and improvements are needed to fully leverage the potential of AI to promote standardization of the clinical diagnosis and treatment of hematological diseases.

Conclusion: Our results serve as a reference point for the clinical diagnosis and treatment of hematological diseases and the development of AI-assisted clinical diagnosis and treatment systems. We offer suggestions for further development of AI in hematology and standardization of clinical diagnosis and treatment.

References

Riley P . Three pitfalls to avoid in machine learning. Nature. 2019; 572(7767):27-29. DOI: 10.1038/d41586-019-02307-y. View

Liu X, Cruz Rivera S, Moher D, Calvert M, Denniston A . [Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI extensionDiretrizes para relatórios de ensaios clínicos com intervenções que utilizam inteligência artificial: a extensão...]. Rev Panam Salud Publica. 2024; 48:e13. PMC: 10863743. DOI: 10.26633/RPSP.2024.13. View

Li C, Zhu B, Chen J, Huang X . Feature genes predicting the FLT3/ITD mutation in acute myeloid leukemia. Mol Med Rep. 2016; 14(1):89-94. PMC: 4918602. DOI: 10.3892/mmr.2016.5260. View

Zhu T, Teschendorff A . Cell-Type Deconvolution of Bulk DNA Methylation Data with EpiSCORE. Methods Mol Biol. 2023; 2629:23-42. DOI: 10.1007/978-1-0716-2986-4_3. View

Sampson D, Parker T, Upton Z, Hurst C . A comparison of methods for classifying clinical samples based on proteomics data: a case study for statistical and machine learning approaches. PLoS One. 2011; 6(9):e24973. PMC: 3182169. DOI: 10.1371/journal.pone.0024973. View

Tung A, Dong L . Malaysian Medical Students' Attitudes and Readiness Toward AI (Artificial Intelligence): A Cross-Sectional Study. J Med Educ Curric Dev. 2023; 10:23821205231201164. PMC: 10501060. DOI: 10.1177/23821205231201164. View

Zhang Z, Wei X . Artificial intelligence-assisted selection and efficacy prediction of antineoplastic strategies for precision cancer therapy. Semin Cancer Biol. 2023; 90:57-72. DOI: 10.1016/j.semcancer.2023.02.005. View

H M van der Velden B, Kuijf H, Gilhuijs K, Viergever M . Explainable artificial intelligence (XAI) in deep learning-based medical image analysis. Med Image Anal. 2022; 79:102470. DOI: 10.1016/j.media.2022.102470. View

Schmidt F, Ranjan B, Xuan Lin Q, Krishnan V, Joanito I, Honardoost M . RCA2: a scalable supervised clustering algorithm that reduces batch effects in scRNA-seq data. Nucleic Acids Res. 2021; 49(15):8505-8519. PMC: 8344557. DOI: 10.1093/nar/gkab632. View

10.

Elshoeibi A, Badr A, Elsayed B, Metwally O, Elshoeibi R, Elhadary M . Integrating AI and ML in Myelodysplastic Syndrome Diagnosis: State-of-the-Art and Future Prospects. Cancers (Basel). 2024; 16(1). PMC: 10778500. DOI: 10.3390/cancers16010065. View

11.

Lu Z, Morita M, Yeager T, Lyu Y, Wang S, Wang Z . Validation of Artificial Intelligence (AI)-Assisted Flow Cytometry Analysis for Immunological Disorders. Diagnostics (Basel). 2024; 14(4). PMC: 10888253. DOI: 10.3390/diagnostics14040420. View

12.

Zhang J, Hu W, Li S, Wen Y, Bao Y, Huang H . Chromosome Classification and Straightening Based on an Interleaved and Multi-Task Network. IEEE J Biomed Health Inform. 2021; 25(8):3240-3251. DOI: 10.1109/JBHI.2021.3062234. View

13.

Fuse K, Uemura S, Tamura S, Suwabe T, Katagiri T, Tanaka T . Patient-based prediction algorithm of relapse after allo-HSCT for acute Leukemia and its usefulness in the decision-making process using a machine learning approach. Cancer Med. 2019; 8(11):5058-5067. PMC: 6718546. DOI: 10.1002/cam4.2401. View

14.

Cubukcu H, Topcu D, Yenice S . Machine learning-based clinical decision support using laboratory data. Clin Chem Lab Med. 2023; 62(5):793-823. DOI: 10.1515/cclm-2023-1037. View

15.

Nazha A, Komrokji R, Meggendorfer M, Jia X, Radakovich N, Shreve J . Personalized Prediction Model to Risk Stratify Patients With Myelodysplastic Syndromes. J Clin Oncol. 2021; 39(33):3737-3746. PMC: 8601291. DOI: 10.1200/JCO.20.02810. View

16.

Chong Y, Thakur N, Lee J, Hwang G, Choi M, Kim Y . Diagnosis prediction of tumours of unknown origin using ImmunoGenius, a machine learning-based expert system for immunohistochemistry profile interpretation. Diagn Pathol. 2021; 16(1):19. PMC: 7953791. DOI: 10.1186/s13000-021-01081-8. View

17.

Singh S, Kumar R, Payra S, Singh S . Artificial Intelligence and Machine Learning in Pharmacological Research: Bridging the Gap Between Data and Drug Discovery. Cureus. 2023; 15(8):e44359. PMC: 10539991. DOI: 10.7759/cureus.44359. View

18.

Lin E, Fuda F, Luu H, Cox A, Fang F, Feng J . Digital pathology and artificial intelligence as the next chapter in diagnostic hematopathology. Semin Diagn Pathol. 2023; 40(2):88-94. DOI: 10.1053/j.semdp.2023.02.001. View

19.

Duetz C, Van Gassen S, Westers T, van Spronsen M, Bachas C, Saeys Y . Computational flow cytometry as a diagnostic tool in suspected-myelodysplastic syndromes. Cytometry A. 2021; 99(8):814-824. PMC: 8453916. DOI: 10.1002/cyto.a.24360. View

20.

Schork N . Artificial Intelligence and Personalized Medicine. Cancer Treat Res. 2019; 178:265-283. PMC: 7580505. DOI: 10.1007/978-3-030-16391-4_11. View